Literature DB >> 11294932

Comparisons of patient self-report, neurologic examination, and functional impairment in MS.

E L Hoogervorst1, L M van Winsen, M J Eikelenboom, N F Kalkers, B M Uitdehaag, C H Polman.   

Abstract

OBJECTIVE: To compare the recently developed Guy's Neurologic Disability Scale (GNDS), based on patient self-report, with both neurologist rating of neurologic examination abnormalities using the Expanded Disability Status Scale (EDSS) and observations of functional impairment on the Multiple Sclerosis Functional Composite (MSFC) in the assessment of disease impact in MS.
METHODS: Two hundred ninety MS patients were recruited at an outpatient clinic. Impairment and disability were assessed using GNDS, EDSS, and MSFC. Correlations between GNDS, EDSS, MSFC, and their corresponding components were studied for the total population, MS phenotypes, and three disability strata.
RESULTS: Mean scores were 4.6 (SD, 2.0) for EDSS, 0.0 (SD, 0.8) for MSFC, and 14.6 (SD, 7.9) for GNDS. Good correlations were found between GNDS and EDSS (r = 0.73), between GNDS and MSFC (r = -0.68), and between different subcategories of the GNDS and EDSS, MSFC, and their corresponding components. Remarkably good correlations were found between lower limb function and all three scales. Poor correlations were also found, especially between different measurements focusing on cognitive function.
CONCLUSION: The good correlations between GNDS and both EDSS and MSFC were mainly due to the importance of spinal-cord-related neurologic functions in all three scoring systems. A marked discrepancy was found for the assessment of cognition between objective measurements and subjective complaints. Because patients' self-reporting correlates well with results of physical examination, GNDS can offer a valuable way to measure disease impact in MS. However, GNDS is not an adequate screen of cognitive dysfunction.

Entities:  

Mesh:

Year:  2001        PMID: 11294932     DOI: 10.1212/wnl.56.7.934

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.

Authors:  Peter J Jongen; Dirk Lehnick; Evert Sanders; Pierette Seeldrayers; Sten Fredrikson; Magnus Andersson; Joachim Speck
Journal:  Health Qual Life Outcomes       Date:  2010-11-15       Impact factor: 3.186

2.  Cortical excitability changes over time in progressive multiple sclerosis.

Authors:  Samar S Ayache; Alain Créange; Wassim H Farhat; Hela G Zouari; Catherine Lesage; Ulrich Palm; Mohammed Abdellaoui; Jean-Pascal Lefaucheur
Journal:  Funct Neurol       Date:  2015 Oct-Dec

3.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

5.  Telemedicine for Monitoring MS Activity and Progression.

Authors:  Nuria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Eugenia Martinez-Hernandez; Albert Saiz
Journal:  Curr Treat Options Neurol       Date:  2015-11       Impact factor: 3.598

6.  Perceived health and geriatric risk stratification: observations from family practice.

Authors:  Daniel Bluestein; Carolyn M Rutledge
Journal:  Can Fam Physician       Date:  2006-05       Impact factor: 3.275

7.  One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.

Authors:  E L J Hoogervorst; M J Eikelenboom; B M J Uitdehaag; C H Polman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

Review 8.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

9.  Self-reported parkinsonian symptoms in the EPIC-Norfolk cohort.

Authors:  Lianna S Ishihara; Kay-Tee Khaw; Robert Luben; Sheila Bingham; Ailsa Welch; Nicholas Day; Carol Brayne
Journal:  BMC Neurol       Date:  2005-08-24       Impact factor: 2.474

10.  Effect of high-dose vitamin D3 intake on ambulation, muscular pain and bone mineral density in a woman with multiple sclerosis: a 10-year longitudinal case report.

Authors:  Barbara M van Amerongen; François Feron
Journal:  Int J Mol Sci       Date:  2012-10-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.